13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q3 2017. See the latest, Q3 2026 →

Reported value

$8.02B

−8.3% on the quarter before

Positions

37

5 new, 9 sold out

Top 10

78.1%

of the value

Est. gain

−$300.4M

on stocks held all quarter

Est. return

−3.8%

on those stocks since Q2 2017

Filed

Nov 13, 2017

On SEC EDGAR ↗

Positions as of Sep 30, 2017, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2017. Striped tiles are options.

Cheniere Energy Inc12%
Synchrony Finl11%
Viasat Inc11%
Qorvo7.9%
Allergan Plc7.6%
Colony Northstar Inc7.5%
Twenty First Centy Fox Inc6.3%
Antero Res Corp5.9%
Pbf Energy Inc5.4%
Theravance Biopharma Inc4.0%
13 others3.1%
Dell Technologies Inc2.9%
Twenty First Centy Fox Inc2.4%
Keryx Biopharmaceuticals Inc2.3%
Cardinal Health Inc2.1%
Express Scripts Hldg Co2.0%
Veritiv Corp1.2%
Atara Biotherapeutics Inc1.1%
Mckesson Corp1.0%
0.7%
0.7%
0.7%
0.6%
0.5%
0.5%

Largest buys

Since Q2 2017, sized at quarter-end prices.

  1. Allergan Plc~$109.0MAdded, 6.8% → 7.6% of the portfolio+531,600 shares
  2. Mckesson Corp~$76.8MNew, 0.0% → 1.0% of the portfolio+500,000 shares
  3. Antero Res Corp~$54.6MAdded, 5.2% → 5.9% of the portfolio+2,741,261 shares
  4. Amc Entmt Hldgs Inc~$52.4MNew, 0.0% → 0.7% of the portfolio+3,565,361 shares
  5. Cardinal Health Inc~$33.5MAdded, 1.8% → 2.1% of the portfolio+500,000 shares
  6. Amerisourcebergen Corp~$15.6MNew, 0.0% → 0.2% of the portfolio+188,850 shares
  7. Pioneer Nat Res Co~$4.3MNew, 0.0% → 0.1% of the portfolio+28,895 shares
  8. Twenty First Centy Fox Inc~$2.7MAdded, 2.3% → 2.4% of the portfolio+106,442 shares
  9. Simply Good Foods Co~$2.5MNew, 0.0% → 0.0% of the portfolio+1,035,146 shares
  10. Theravance Biopharma Inc~$1.2MAdded, 4.2% → 4.0% of the portfolio+35,177 shares

Largest sells

Since Q2 2017, sized at quarter-end prices.

  1. Qualcomm~$288.0MSold out, 3.3% → 0.0% of the portfolio−5,216,000 shares
  2. Dell Technologies Inc~$200.7MCut, 3.9% → 2.9% of the portfolio−2,600,000 shares
  3. Avis Budget Group~$112.8MCut, 1.2% → 0.5% of the portfolio−2,963,100 shares
  4. Spirit Rlty Cap Inc New~$66.7MSold out, 0.8% → 0.0% of the portfolio−9,000,000 shares
  5. Silver Run Acquisition~$45.5MCut, 0.8% → 0.3% of the portfolio−4,466,200 shares
  6. Conyers Pk Acquisition~$43.7MSold out, 0.5% → 0.0% of the portfolio−3,712,500 shares
  7. Liberty Media Corp Delaware~$31.2MSold out, 0.4% → 0.0% of the portfolio−1,303,482 shares
  8. Credit Accep Corp Mich~$25.4MSold out, 0.3% → 0.0% of the portfolio−98,700 shares
  9. Theravance Inc~$15.5MSold out, 0.2% → 0.0% of the portfolio−16,980,000 shares
  10. ChipMOS Technologies~$8.9MCut, 0.8% → 0.7% of the portfolio−461,563 shares

Holdings

As of Sep 30, 2017; changes in shares since Jun 30, 2017.

Positions, sorted by share of the portfolio
HoldingValue
Cheniere Energy IncCOM NEW · shares 0% · price −7.5%11.6%$933.5M−$76.1M
Synchrony FinlCOM · shares 0% · price +4.1%11.3%$909.6M+$36.0M
Viasat IncCOM · shares 0% · price −2.8%10.5%$846.3M−$24.7M
QorvoCOM · shares 0% · price +11.6%7.9%$636.1M+$66.2M
Allergan PlcSHS · shares +22% · price −15.7%7.6%$607.5M−$92.8M
Colony Northstar IncCL A COM · shares 0% · price −10.9%7.5%$601.7M−$73.3M
Twenty First Centy Fox IncCL A · shares 0% · price −6.9%6.3%$504.8M−$37.5M
Antero Res CorpCOM · shares +13% · price −7.9%5.9%$475.9M−$36.2M
Pbf Energy IncCL A · shares 0% · price +24.0%5.4%$434.1M+$84.1M
Theravance Biopharma IncCOM · shares +0.4% · price −14.1%4.0%$318.7M−$51.9M
Dell Technologies IncCOM CL V · shares −46% · price +26.3%2.9%$235.7M+$49.1M
Twenty First Centy Fox IncCL B · shares +1.5% · price −7.5%2.4%$190.4M−$15.1M
Keryx Biopharmaceuticals IncCOM · shares 0% · price −1.8%2.3%$183.1M−$3.4M
Cardinal Health IncCOM · shares +25% · price −14.1%2.1%$169.3M−$22.3M
Express Scripts Hldg CoCOM · shares 0% · price −0.8%2.0%$161.9M−$1.3M
Veritiv CorpCOM · shares +0.3% · price −27.8%1.2%$99.2M−$38.1M
Atara Biotherapeutics IncCOM · shares 0% · price +18.2%1.1%$88.7M+$13.7M
Mckesson CorpCOM · shares New0.96%$76.8M—
Paratek Pharmaceuticals IncCOM · shares 0% · price +4.2%0.75%$60.1M+$2.4M
ChipMOS TechnologiesSPONSORED ADR · shares −13% · price −2.3%0.73%$58.9M−$1.4M
Amc Entmt Hldgs IncCL A COM · shares New0.65%$52.4M—
Gty Technology Holdings IncUNIT 99/99/9999 · shares 0% · price 0.0%0.57%$46.0M$0.00
Centennial Resource Dev IncCL A · shares 0% · price +14.5%0.52%$42.1M+$5.3M
Avis Budget GroupCOM · shares −74% · price +39.6%0.49%$39.5M+$11.2M
Forward Pharma A/SSPONSORED ADR · shares +1.6% · price −70.1%0.49%$39.2M−$90.8M
Total 37 positions100%$8.02B−$300.4M

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q2 2017 to Q3 2017: 31 stocks held throughout, down $300.4M (−3.8%).

  1. Pbf Energy Inc+$84.1M+24%
  2. Qorvo+$66.2M+12%
  3. Dell Technologies Inc+$49.1M+26%
  4. Synchrony Finl+$36.0M+4%
  5. Atara Biotherapeutics Inc+$13.7M+18%
  6. Theravance Biopharma Inc−$51.9M−14%
  7. Colony Northstar Inc−$73.3M−11%
  8. Cheniere Energy Inc−$76.1M−8%
  9. Forward Pharma A/S−$90.8M−70%
  10. Allergan Plc−$92.8M−16%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free